Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07180355 · ClinicalTrials.gov registry record · Phase 1
A Study of SGT-212 Gene Therapy in Friedreich's Ataxia
A Phase 1 study of Friedreich's Ataxia (FA), sponsored by Solid Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT07180355: Recruiting Phase 1 study of Friedreich's Ataxia (FA), sponsored by Solid Biosciences.
NCT07180355 is a Phase 1 study of Friedreich's Ataxia (FA) that is actively recruiting participants, run by Solid Biosciences. The registered enrollment target is 10 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07180355, a Phase 1 study of Friedreich's Ataxia (FA), is actively recruiting participants, sponsored by Solid Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA. All participants will receive SGT-212 and will be enrolled in the study for approximately 5 years.
Conditions Studied
Interventions
- DRUG SGT-212
Study Locations (3)
California
- The University of California, Los Angeles (UCLA) - Los Angeles
Ohio
- The Ohio State University - Columbus
Pennsylvania
- The Children's Hospital of Philadelphia (CHOP) - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-10-22 |
| Est. Completion | 2032-02-29 |
| Phase | Phase 1 |
What NCT07180355 shows while recruiting
NCT07180355 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Friedreich's Ataxia (FA) appearing as the primary indexed condition, and to 1 intervention - of which SGT-212 is the first listed.
NCT07180355 reports a single indexed study location in California, Ohio, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07180355 about?
NCT07180355 is a clinical study titled "A Study of SGT-212 Gene Therapy in Friedreich's Ataxia". This is a phase 1b, first in-human, open-label, dose-finding study investigating the safety and tolerability of SGT-212 in participants with Friedreich's ataxia (FA). It will be delivered via dual intradentate nucleus (IDN) and intravenous (IV) administration to participants with FA. All participan...
What is the current status of trial NCT07180355?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2025-10-22. Estimated completion is 2032-02-29.
What conditions does trial NCT07180355 study?
This clinical trial studies the following conditions: Friedreich's Ataxia (FA).
What interventions are being tested in trial NCT07180355?
The interventions under investigation include: SGT-212 (DRUG).
Who is sponsoring clinical trial NCT07180355?
This trial is sponsored by Solid Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07180355 being conducted?
This trial has 3 study locations across California, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07180355's enrollment target sits among peer trials
10 1913th of 2000 higher than 46 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI